GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom.
Bioorg Med Chem Lett. 2010 Jan 15;20(2):618-22. doi: 10.1016/j.bmcl.2009.11.077. Epub 2009 Nov 20.
Structure and property based drug design was exploited in the synthesis of sulfonamidopyrrolidin-2-one-based factor Xa inhibitors, incorporating neutral and basic monoaryl P4 groups, ultimately producing potent inhibitors with effective levels of anticoagulant activity and extended oral pharmacokinetic profiles. However, time dependant inhibition of Cytochrome P450 3A4 was a particular issue with this series.
基于结构和性质的药物设计被应用于磺酰胺基吡咯烷-2-酮类因子 Xa 抑制剂的合成中,其中包含中性和碱性单芳基 P4 基团,最终得到了具有有效抗凝活性和延长口服药代动力学特征的强效抑制剂。然而,该系列药物存在细胞色素 P450 3A4 时间依赖性抑制的问题。